Confronting Cancer as a Community
ConditionColorectal Carcinoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Southern California
About this trial
This study aims to better understand the cause of colorectal cancer and how to find the best treatment for Hispanic patients with colorectal cancer. The genetic information in the blood and tissues may explain why patients who have the same type of cancer and receive the same treatment do not always have the same results. By combining genetic (certain qualities or traits passed from parents to offspring) information with clinical data, such as the responses of different kinds of cancers to different treatments, this study could lead to more knowledge about why certain cancers occur and why they respond differently to treatments. Information gathered from this study may help researchers match treatments to the genetics of each patient and the genetic changes in their tumor. This approach is known as personalized medicine.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Self-reported Hispanic ethnicity
Diagnosed with colon or rectal cancer (at any time and stage; lifetime diagnosis and in survival are eligible)
Has a tumor tissue sample archived or plans to have tissue archived from a standard care procedure
Age >= 18 years
Disqualifiers
Inability to understand and the willingness to sign a written informed consent
Trial design
Design model
Parallel
Treatments tested in this trial
Usual Care Educational Materials
Other interventionStandard education materials
Intervention Educational Materials
Other interventionCoGenes educational materials with video.
Treatment groups
500 Participants
are divided into 2 treatment groupsGroup A: Arm 1: Usual CareExperimental treatment 1 intervention
Group B: Arm 2: InterventionExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Time to recurrence (TTR)
Determined from time of registration to date of documented event such as treatment-related deaths, second same or other primary cancers, and deaths from other cancers.
Time frame
Assessed up to 6 years2
Progression free survival (PFS)
Determined from start of treatment to time of progression or death (whichever comes first).
Time frame
Assessed up to 6 years3
Overall survival (OS)
Determined from start of treatment until death due to any cause.
Time frame
Assessed up to 6 years4
Changes in genomic knowledge
The KnowGene scale will be used. Score Range = 0-16. Higher score indicates higher knowledge.
Time frame
Baseline, at 2 weeks, and at 12-month follow upSponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Southern California
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov